Lercanidipin Actavis

Lercanidipine, the active ingredient in Lercanidipin Actavis, is a calcium channel blocker presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Lercanidipin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of arterial hypertension. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth, especially on the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: often related to blood pressure lowering. - Tachycardia: increased heart rate. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angio‑edema: swelling of lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria.

Before initiating therapy, consider the following safety measures. - Cardiovascular assessment: evaluate baseline blood pressure and heart rate. - Concomitant antihypertensives: monitor for additive hypotensive effects. - Liver impairment: use with caution in patients with hepatic disease. - Elderly patients: start at the lowest effective dose and monitor closely. - Pregnancy and lactation: avoid unless clearly indicated by a physician. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive hypotension. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Simvastatin: increased risk of statin‑related myopathy.